Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Longeveron Inc
(NQ:
LGVN
)
1.280
-0.010 (-0.78%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Longeveron Inc
< Previous
1
2
3
Next >
Hidden Belly Fat Could Be a Precursor of Alzheimer’s Onset Years Later
November 30, 2023
Via
Investor Brand Network
Longeveron Inc. (NASDAQ: LGVN) Encouraged by Positive Results from Phase 2a Trial in Patients with Mild AD; Explores Paths Forward for the Development of Lomecel-B(TM)
November 21, 2023
Via
Investor Brand Network
Study Links Cat Parasite to Accelerated Frailty in Aging People
November 16, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Featured in Bell2Bell Podcast
November 14, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Study Survival Data Reported at AHA’s 2023 Scientific Sessions
November 13, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Announces 2023 Results, Provides Corporate Update
November 10, 2023
Via
Investor Brand Network
Sex Hormones Could Influence Alzheimer’s Development, Researchers Say
November 06, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Announces Plans to Release Q3 2023 Financial Report, Host Corporate Update Call
November 03, 2023
Via
Investor Brand Network
Longeveron Inc. (NASDAQ: LGVN) Validates Safety and Therapeutic Potential of its Lomecel-B(TM) Lead Investigational Product in its CLEAR MIND Phase 2a Clinical Trial
October 30, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Top-Line Results from Phase 2a Trial Spotlighted in Latest NNA Release
October 24, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Closes on $4M Registered Direct Offering
October 16, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Enters into $4M Registered Direct Offering
October 12, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Reports Top-Line Results for Phase 2a Lomecel-B Clinical Trial
October 05, 2023
Via
Investor Brand Network
Longeveron Inc. (NASDAQ: LGVN) Eyeing Global HLHS, in addition to Alzheimer’s Disease, and Aging-Related Frailty Treatment Markets with Lomecel-B(TM), its Lead Investigational Product
September 27, 2023
Via
Investor Brand Network
Longeveron Inc. (NASDAQ: LGVN) to Discuss Its Cellular Therapy Programs, Clinical Trial Progress at the 25th Annual H.C. Wainwright Global Investment Conference
September 14, 2023
Via
Investor Brand Network
Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market
September 12, 2023
By David Willey, Benzinga
Via
TheNewswire.com
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) CEO Releases Stockholder Letter
September 11, 2023
Via
Investor Brand Network
Longeveron Inc. (NASDAQ: LGVN) Is ‘One to Watch’
September 08, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Announces ELPIS 1 Trial Data Accepted for AHA Presentation, IBN Partnership
September 07, 2023
Via
Investor Brand Network
Upcoming Phase 2 Data Expected For Longeveron’s (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer’s Sector – What To Look For
September 07, 2023
By David Willey, Benzinga
Via
TheNewswire.com
BioMedNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Present at Upcoming H.C. Wainwright Global Investment Conference
September 05, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Announces Participation at Upcoming National Investment Banking Association Conference
August 30, 2023
Via
Investor Brand Network
Longeveron Announces Key Additions To Its Leadership Team and Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions
August 08, 2023
By David Willey, Benzinga
Via
TheNewswire.com
HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron’s Lomecel-B Improve Outcomes?
July 07, 2023
By David Willey, Benzinga
Via
TheNewswire.com
Exposures
Product Safety
Cognitive Drugs Market Expected Reach Revenues Of $21 Billion in 2027
April 13, 2022
Palm Beach, FL – April 13, 2022 – FinancialNewsMedia.com News Commentary – Dementia is the loss of cognitive functioning, thinking, remembering, reasoning, and behavioral abilities to such an extent...
Via
FinancialNewsMedia
Exposures
COVID-19
R&D Efforts for Alzheimer’s Therapies on the Rise with over 120 Drugs in Development
March 31, 2022
Palm Beach, FL – March 31, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease. It is the most common cause of dementia...
Via
FinancialNewsMedia
Alzheimer’s Disease Expected to Triple by 2050 While the Development Process for Potential Drug Candidates Increases
January 05, 2022
Palm Beach, FL – January 5, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is the most common reason of progressive dementia in the elderly population. There has been an...
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Longeveron Inc. (NASDAQ:LGVN) Long Term Investor Notice: Investigation of Potential Wrongdoing
December 17, 2021
San Diego, CA -- (SBWIRE) -- 12/17/2021 -- An investigation on behalf of current long-term investors in shares of Longeveron Inc. (NASDAQ:LGVN) concerning potential breaches of fiduciary duties by...
Via
SBWire
Systemic Mastocytosis Treatments Gain Hope Due To Increasing Novel Treatment Options
December 21, 2021
Palm Beach, FL –December 21, 2021 – FinancialNewsMedia.com News Commentary – Systemic mastocytosis is rare disease which affects very few people and it causes due to C-kit mutation which leads to...
Via
FinancialNewsMedia
Exposures
Product Safety
Systemic Lupus Erythematosus Treatment Market Projected To Reach $3.56 Billion By 2027
December 08, 2021
Palm Beach, FL –December 8, 2021 – FinancialNewsMedia.com News Commentary – Systemic Lupus Erythematosus is also known as lupus. It is an autoimmune disease that affects all parts of your body. The...
Via
FinancialNewsMedia
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.